Kura Oncology, Inc.
KURA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.1B
$12.89
▲ +1.90%
P/E
-3.82
Mkt Cap
$1.1B
52-Wk Range
$7.36–$13.90
52-Week Range
$7.36 - $13.90
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 62.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Targeted small molecule approach addressing genetically defined cancer subtypes with precision medicine focus
- Strategic partnership with Novartis providing clinical expertise, resources, and commercialization potential
- Focused pipeline strategy reducing development complexity while maximizing probability of clinical success
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Moderate growth ahead
Clinical trial progression of ziftomenib in AML and ALL with potential for accelerated regulatory pathways
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+43.7% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying KURA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 3, 2026
AUG 12, 2026
Reported EPS of -$0.77 vs -$0.88 consensus (+12.2% surprise). Revenue of $20.9M vs $20.2M expected (+3.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+12.2%
Revenue trend · last 8Q
—
—
—
—
—
-68%
+29%
+37%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$53.9M
$14.1M
$15.3M
$20.8M
$17.3M
$18.3M
$20.9M
Margins · last 8Q
Gross
98.8%
Operating
—
Profit
-327.3%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 24, 2026
vs Industry
How KURA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related